• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Administering naloxone for opioid overdose reversal in out-of-hospital settings appears to be safe and effective

byEvelyn NguyenandDeepti Shroff Karhade
December 6, 2017
in Chronic Disease, Emergency, Psychiatry, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. For reversing opioid overdose, intranasal naloxone of a higher concentration (2 mg/mL) seems to have a similar efficacy to intramuscular naloxone.

2. Lack of transport to a health care facility after successful naloxone reversal seems to be associated with low serious adverse events and death rates, but no comparisons were made to a transport group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In the United States, opioid overdose is the top cause of death related to injury.  Outside the hospital, naloxone is often used to treat opioid overdose.  Although guidelines for such use exists, there still remain some uncertainties, which this systematic review sought to address.  Researchers aimed to synthetize data regarding the effects on mortality of naloxone administration routes and dosages on people suspected to have overdosed on opioids in a nonhospital setting.  The authors also evaluated the necessity for transport to a facility for care after an overdose was reversed with naloxone.  After reviewing 13 eligible studies, researchers found that for reversing opioid overdose, intranasal naloxone of a higher concentration (2 mg/mL) had a similar efficacy to intramuscular naloxone.  Lack of transport after naloxone reversal appeared to be linked to a low rate of severe harm.  However, no study assessed the risk of lack of transport versus transport.  The authors suggest that further research is required to determine the best administration route and optimal dose of naloxone.

A strength of this study is that it may assist with emergency medical services (EMS) naloxone use guidelines. Limitations of the study include the low number of studies, some methodological inadequacies, and lack of studies assessing highly concentrated intranasal reformulations or autoinjectors that have been recently approved by the U.S. Food and Drug Administration (FDA).

Click to read the study in Annals of Internal Medicine

Relevant Reading: Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access

RELATED REPORTS

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

Patient and prescription factors associated with overdose after initiating opioids

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

In-Depth [systematic review]: In this study, researchers used the Cochrane Central Register of Controlled Trials, Ovid MEDLINE, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), materials from the FDA, and reference lists to find randomized trials and cohort studies that compared various doses of naloxone, routes of administration, and lack of transport versus transport after naloxone reversal.  The authors found 13 eligible studies, including 4 cohort studies and 3 randomized controlled trials that evaluated various routes of administration. Of these, 1 trial found that for reversing opioid overdose, intranasal naloxone of a higher concentration (2 mg/mL) had a similar efficacy (with no adverse event differences) to intramuscular naloxone.  Another trial found that intranasal naloxone at a lower concentration (2 mg/5 mL) was not as effective as intramuscular naloxone but was linked to a reduced agitation risk.  Both trials had the same total dose of 2 mg.  There was not enough evidence to make conclusions about other administration routes.  Six studies reported low serious adverse events and death rates (0% to 1.25%) in patients who were not transported after successful naloxone reversal.  However, there was no transported patient group for comparison.  Considering that people who were not transported probably are at a decreased risk for complications related to opioid overdose compared to patients who were transported, this makes interpretation of this data difficult.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: drug abusenaloxoneopioid epidemic
Previous Post

Brodmann area 25 may have role in causing peri-ictal systolic hypotension in patients with epilepsy

Next Post

Biennial biopsies may be adequate for men under active surveillance for prostate cancer

RelatedReports

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Chronic Disease

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

March 30, 2022
Publication of pneumonia antibiotic guidelines changed prescribing trends
Emergency

Patient and prescription factors associated with overdose after initiating opioids

February 1, 2022
Social networks play key roles in parental vaccination decisions
Chronic Disease

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

November 1, 2021
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Wellness

United States providers increased prescribing of buprenorphine/naloxone

September 28, 2021
Next Post
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Biennial biopsies may be adequate for men under active surveillance for prostate cancer

High readmission rates after revascularization for peripheral arterial disease

Digital imaging detects sight-threatening retinopathy of prematurity

Long-term comorbidities in extremely preterm infants with cerebral palsy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options